163 related articles for article (PubMed ID: 23095281)
1. Subclinical vasculitis as a potential mechanism to explain the heightened cardiovascular risk in rheumatoid arthritis.
Fayad ZA; Greenberg JD; Bucerius J
Circulation; 2012 Nov; 126(21):2449-51. PubMed ID: 23095281
[No Abstract] [Full Text] [Related]
2. Response to letter regarding article, ''anti-tumor necrosis factor-α therapy reduces aortic inflammation and stiffness in patients with rheumatoid arthritis''.
Circulation; 2013 Jul; 128(1):e11. PubMed ID: 23980280
[No Abstract] [Full Text] [Related]
3. Letter by Lensen et al regarding article, "anti-tumor necrosis factor-α therapy reduces aortic inflammation and stiffness in patients with rheumatoid arthritis".
Lensen KJ; van Sijl AM; Smulders YM
Circulation; 2013 Jul; 128(1):e10. PubMed ID: 23817487
[No Abstract] [Full Text] [Related]
4. Anti-tumor necrosis factor-α therapy reduces aortic inflammation and stiffness in patients with rheumatoid arthritis.
Mäki-Petäjä KM; Elkhawad M; Cheriyan J; Joshi FR; Ostör AJ; Hall FC; Rudd JH; Wilkinson IB
Circulation; 2012 Nov; 126(21):2473-80. PubMed ID: 23095282
[TBL] [Abstract][Full Text] [Related]
5. Should anti-tumor necrosis factor-alpha be the first therapy for rheumatoid vasculitis?
Garcia-Porrua C; Gonzalez-Gay MA; Quevedo V
J Rheumatol; 2006 Feb; 33(2):433; author reply 433-4. PubMed ID: 16465676
[No Abstract] [Full Text] [Related]
6. Improved rheumatoid digital vasculitis in a patient treated with TNFalpha agent blocking (infliximab).
Benucci M; Li Gobbi F; Saviola G; Manfredi M
Rheumatol Int; 2008 Oct; 28(12):1253-5. PubMed ID: 18493770
[TBL] [Abstract][Full Text] [Related]
7. Isolated digital vasculitis in a patient with rheumatoid arthritis: good response to tumour necrosis factor alpha blocking treatment.
den Broeder AA; van den Hoogen FH; van de Putte LB
Ann Rheum Dis; 2001 May; 60(5):538-9. PubMed ID: 11302883
[TBL] [Abstract][Full Text] [Related]
8. The effect of tumor necrosis factor-α antagonists on arterial stiffness in rheumatoid arthritis: a literature review.
Dulai R; Perry M; Twycross-Lewis R; Morrissey D; Atzeni F; Greenwald S
Semin Arthritis Rheum; 2012 Aug; 42(1):1-8. PubMed ID: 22475245
[TBL] [Abstract][Full Text] [Related]
9. The effects of TNF-alpha inhibitor therapy on arterial stiffness and endothelial dysfunction in rheumatoid arthritis: a meta-analysis.
Mathieu S; Couderc M; Pereira B; Soubrier M
Semin Arthritis Rheum; 2013 Dec; 43(3):e1-2. PubMed ID: 23810615
[No Abstract] [Full Text] [Related]
10. Intestinal necrosis in a patient with rheumatoid arthritis receiving anti-TNF treatment.
Ruppert M; De Clerck L; van Offel J; Hubens G; Balliu L; Vaneerdeweg W
Acta Chir Belg; 2006; 106(2):225-7. PubMed ID: 16761484
[TBL] [Abstract][Full Text] [Related]
11. Tumor necrosis factor-alpha blockade and the risk of vasculitis.
Guillevin L; Mouthon L
J Rheumatol; 2004 Oct; 31(10):1885-7. PubMed ID: 15468348
[No Abstract] [Full Text] [Related]
12. No significant change in arterial stiffness in RA after 6 months and 1 year of rituximab treatment.
Mathieu S; Pereira B; Dubost JJ; Lusson JR; Soubrier M
Rheumatology (Oxford); 2012 Jun; 51(6):1107-11. PubMed ID: 22328565
[TBL] [Abstract][Full Text] [Related]
13. Foot ulcers caused by rheumatoid vasculitis in a patient with rheumatoid arthritis undergoing etanercept treatment.
Murosaki T; Nagashima T; Aoki Y; Imai Y; Iwamoto M; Minota S
Intern Med; 2012; 51(22):3181-3. PubMed ID: 23154729
[TBL] [Abstract][Full Text] [Related]
14. Vasculitis in rheumatoid arthritis.
Turesson C; Matteson EL
Curr Opin Rheumatol; 2009 Jan; 21(1):35-40. PubMed ID: 19077716
[TBL] [Abstract][Full Text] [Related]
15. Rheumatoid aortitis: a rarely recognized but clinically significant entity.
Gravallese EM; Corson JM; Coblyn JS; Pinkus GS; Weinblatt ME
Medicine (Baltimore); 1989 Mar; 68(2):95-106. PubMed ID: 2921941
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular magnetic resonance characterization of myocardial and vascular function in rheumatoid arthritis patients.
Ntusi NAB; Francis JM; Gumedze F; Karvounis H; Matthews PM; Wordsworth PB; Neubauer S; Karamitsos TD
Hellenic J Cardiol; 2019; 60(1):28-35. PubMed ID: 29369795
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis.
Puéchal X; Miceli-Richard C; Mejjad O; Lafforgue P; Marcelli C; Solau-Gervais E; Steinfeld S; Villoutreix C; Trèves R; Mariette X; Guillevin L;
Ann Rheum Dis; 2008 Jun; 67(6):880-4. PubMed ID: 18037625
[TBL] [Abstract][Full Text] [Related]
18. [Infections and lymphoma during prolonged immunosuppression in vascular diseases].
Guillevin L
Rev Med Interne; 2005 Oct; 26 Spec No 1():35-8. PubMed ID: 16475263
[No Abstract] [Full Text] [Related]
19. IgA Vasculitis Developed as an Adverse Effect of Tofacitinib Taken for Rheumatoid Arthritis.
Itoh I; Kasuno K; Yamamoto C; Takahashi N; Shimizu H; Ojima T; Hayashi S; Kimura H; Iwano M
Intern Med; 2020 Mar; 59(6):817-821. PubMed ID: 31813912
[TBL] [Abstract][Full Text] [Related]
20. Effect of 1-year anti-TNF-α therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: a controlled study.
Angel K; Provan SA; Fagerhol MK; Mowinckel P; Kvien TK; Atar D
Am J Hypertens; 2012 Jun; 25(6):644-50. PubMed ID: 22378036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
